CLAIM CARD
This synthesis maps 41 included sources on Immune age across 6 outcome classes and 382 cross-study disagreements. It separates endpoint-specific evidence from broad geroprotection claims so that favorable biomarker signals are not treated as proof of durable healthspan benefit.
Evidence grade: exploratory
Contradiction status: none
Publication: bd4ddec9-e10e-445f-bf0b-a5399dfae223
Provenance: Derivation Web chain
Citation Support
source_1Jongsma 2023source_2Xie 2025source_3Wallen 2024source_4Hoang 2025source_5Boudhabhay 2026